Results 181 to 190 of about 1,392 (217)

Unveiling nuclear localization signals in human arginine deiminase proteins

Protein Science, Volume 35, Issue 4, April 2026.
Abstract Arginine iminohydrolases are a family of enzymes involved in the conversion of arginine to citrulline. There are five isoforms in humans (PADI1, 2, 3, 4, and 6). Some of them are observed experimentally in the cytoplasm and in the nucleus of the cell; for moving to the latter location, they must pass through the cell nuclear membrane by using ...
José L. Neira, Olga Abian, Adrián Velazquez‐Campoy, Bruno Rizzuti   +3 more
wiley   +1 more source

Analysis of Thermal Dynamics of Floating Photovoltaic Systems

Solar RRL, Volume 10, Issue 6, 29 March 2026.
A scalable methodology couples computational fluid dynamics‐derived wind decay functions with a dynamic heat transfer model to capture spatial temperature variations across large floating photovoltaic systems and is validated with data from the Netherlands floating photovoltaic systems (FPV) site.
A. Kaul, N. van den Nobelen, S. Golroodbari, W. G. J. H. M. van Sark   +3 more
wiley   +1 more source

Radiopharmaceutical: An Update and Comparison of Preclinical Investigation Result of Alpha and Beta Emitter Radioisotope. [PDF]

Drug Des Devel Ther
Luhung A, Hasanah AN, Ramdhani D.
europepmc   +1 more source

Recommendations on the Clinical Application and Future Potential of α-Particle Therapy: A Comprehensive Review of the Results from the SECURE Project. [PDF]

Pharmaceuticals (Basel)
Di Iorio V, Sarnelli A, Boschi S, Sansovini M, Genovese RM, Stefanescu C, Ghizdovat V, Jalloul W, Young J, Sosabowski J, Kolenc P, Roberts R, With G, Visvikis D, Mikolajczak R.   +14 more
europepmc   +1 more source

Refining the clinical utility of [¹⁷⁷Lu]Lu/[²²⁵Ac]Ac-PSMA tandem RLT in patients with metastatic castration resistant prostate cancer. [PDF]

Eur J Nucl Med Mol Imaging
Widjaja L, Hornfeck J, Siegmund SC, Gildehaus FJ, Schmidt-Hegemann NS, Wenter V, Sheikh GT, Klimek K, Casuscelli J, Stief CG, Zacherl MJ, Werner RA.   +11 more
europepmc   +1 more source

Trop-2.2 directed radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a pancreatic cancer model. [PDF]

Clin Cancer Res
Pratt EC, Bauer D, Carter LM, Cornejo M, Carrasco SE, Kaminsky S, De Gregorio R, Loor A, Friedl O, Bolaender A, Chao G, Castanares MA, Collins EC, Lewis JS.   +13 more
europepmc   +1 more source

March and April 2026 global highlights

Hong Kong Journal of Emergency Medicine, Volume 33, Issue 2, April 2026.
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Challenges and opportunities in developing Actinium-225 radiopharmaceuticals

Nuclear Medicine Communications, 2022
Actinium-225 (225Ac) has emerged as a promising therapeutic radioisotope for targeted alpha therapy. It emits net four alpha particles during its decay to stable daughter bismuth-209, rightly called an in-vivo nano-generator. Compared to the worldwide demand of 225Ac, the amount produced via depleted thorium-229 sources is minimal, making it an ...
Deeksha, Dhiman, Rakhee, Vatsa, Ashwani, Sood   +2 more
openaire   +2 more sources

Generator of actinium-225

Journal of Radioanalytical and Nuclear Chemistry Articles, 1996
Dependence upon pH of Ac and Th distribution coefficients between the cation exchange resin and buffer citrate solutions had been investigated; the optimal conditions are suggested for effective separation of the elements in this system. These results are in successful accordance with such conditions calculated on the basement of Ac and Th citrate ...
V. Tsoupko-Sitnikov, Yu. Norseev, V. Khalkin   +2 more
openaire   +1 more source

Computer-Assisted Design of Macrocyclic Chelators for Actinium-225 Radiotherapeutics

Inorganic Chemistry, 2020
Actinium-225 (225Ac) is an excellent candidate for targeted radiotherapeutic applications for treating cancer, because of its 10-day half-life and emission of four high-energy α2+ particles. To harness and direct the energetic potential of actinium, strongly binding chelators that remain stable in vivo during biological targeting must be developed ...
Amanda Morgenstern, Laura M. Lilley, Benjamin W. Stein, Stosh A. Kozimor, Enrique R. Batista, Ping Yang   +5 more
openaire   +2 more sources